Welcome to our dedicated page for Reata Pharmaceut news (Ticker: RETA), a resource for investors and traders seeking the latest updates and insights on Reata Pharmaceut stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Reata Pharmaceut's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Reata Pharmaceut's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) announced its participation in the Barclays Global Healthcare Conference from March 14-16 in Miami, Florida. Manmeet Soni, President, COO, and CFO, will engage in a fireside chat at the event. The company is focused on developing innovative therapies for severe diseases and has made significant strides with the first FDA-approved product for Friedreich’s ataxia. Additionally, Reata is advancing its pipeline, including bardoxolone methyl for chronic kidney disease and cemdomespib for diabetic neuropathic pain, although both drugs remain investigational and unproven by regulatory standards.
Reata Pharmaceuticals has announced FDA approval for SKYCLARYS (omaveloxolone) to treat Friedreich’s ataxia in adults and adolescents over 16. This marks the first specific therapy for this ultra-rare, progressive neuromuscular disease affecting approximately 5,000 patients in the U.S. The FDA also granted a rare pediatric disease priority review voucher. The approval is based on data from the MOXIe Part 2 trial, showing significant efficacy and safety. Commercial supply of SKYCLARYS is expected in Q2 2023, alongside the launch of the REACH patient support program.
Reata Pharmaceuticals, Inc. (NASDAQ: RETA) announced its participation in two upcoming healthcare conferences in New York: the Guggenheim 2022 Immunology & Neurology Conference on November 14-15 and the Stifel 2022 Healthcare Conference on November 15-16. As a clinical-stage biopharmaceutical company, Reata focuses on developing innovative therapeutics for serious diseases, with lead candidates omaveloxolone and bardoxolone targeting the Nrf2 transcription factor to combat inflammation and oxidative stress. However, their safety and efficacy remain unverified.
